Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

May 23, 2024 5:15 PM

OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months) and overall survival (median 14.3 months) support continued development of mitazalimab in a randomized confirmatory Phase 3 trialBiomarker analysis demonstrates correlation of mitazalimab-induced immune activation with clinical...

Read more

MMJ to Summons DEA Heads - Milgram DEA Director Removed from Marijuana Rescheduling Issue

May 23, 2024 3:15 PM

During a recent congressional hearing, Anne Milgram , Director of the Drug Enforcement Administration (DEA), passionately addressed the alarming surge in illegal fentanyl-related deaths . Her plea for action against this epidemic resonated widely. However, amidst this urgency, a significant contradiction emerges- the DEA's hindrance of marijuana research and drug development. DEA vs. Marijuana Research: A Troubling Double StandardDespite the...

Read more

RNAConnect, Inc. Formally Launches Today to Drive RNA Analysis With Innovative Research Tools

May 23, 2024 9:00 AM

BRANFORD, CO / ACCESSWIRE / May 23, 2024 / RNAConnect, a pioneering life science reagent company, officially launches today, promising groundbreaking solutions for exploring the real-world diversity of RNA sequence and structure. RNAConnect RNAConnect full-color horizontal company logo RNAConnect was founded by innovators in the RNA community, for innovators in the RNA community. It is anchored by the belief that better enzymatic tools for...

Read more

Longwood Healthcare Leaders Spring MIT to Convene Life Science Thought Leaders at MIT Koch Institute

May 23, 2024 7:45 AM

BOSTON, MA / ACCESSWIRE / May 23, 2024 / Longwood Fund, an early-stage life science venture firm, will convene top biopharmaceutical leaders for two days of discussion and networking at its annual Longwood Healthcare Leaders Spring MIT forum, co-hosted by Koch Institute Professors Phil Sharp and Bob Langer and held at MIT's Koch Institute, June 17-18, 2024.LHL.Logo The industry-leading meeting focuses on a broad spectrum of topics affecting the...

Read more

Moolec Science to Host Third Quarter Fiscal Year 2024 Business Update Conference Call

May 23, 2024 7:00 AM

LUXEMBOURG / ACCESSWIRE / May 23, 2024 / Moolec Science SA (NASDAQ:MLEC)("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today that it will release its Business Update for the Third Quarter Fiscal Year 2024 on Thursday, May 30, 2024, before the market opens. Moolec Logo Moolec Science Logo Moolec's Chief Executive Officer Gastón Paladini, Chief...

Read more

Xenetic Biosciences, Inc. Announces Executive Leadership Transition

May 22, 2024 5:00 PM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024."I am a strong believer in the potential of our innovative immune-oncology technologies...

Read more

InDevR Introduces Latest Solution for Influenza Vaccine Manufacturers, OmniFlu HA, to Simplify Vaccine Testing and Speed Time to Market

May 22, 2024 3:30 PM

Validated, off-the-shelf kit for multiplexed seasonal hemagglutinin (HA) detection and quantification addresses the unique challenges faced by vaccine developers and manufacturers.BOULDER, CO / ACCESSWIRE / May 22, 2024 / InDevR, Inc., a global leader in vaccine testing and multiplexed assay development for vaccine manufacturers, is excited to announce the launch of OmniFlu HA, a validated, off-the-shelf kit for seasonal influenza vaccine...

Read more

Everfur Launches Fur-Forward Diagnostics Kit: Pioneering Pet Health Monitoring With Advanced Metabolomics

May 22, 2024 10:00 AM

NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Everfur announces the debut of its groundbreaking product: the Fur-Forward Diagnostics Kit. With just a sample of your pets' fur, Everfur analyzes their unique molecules to help determine fur quality, brain health, digestion, immunity, and potential disease risks. Inspired by the journey of Daisy, the beloved feline companion of Fayzan Chaudhry, CEO of Everfur and a PhD Candidate, this innovative...

Read more

Archetype Discovers Drugs to Improve Patient Outcomes in Lung Cancer Using a Generative Chemogenomic Screen of Billions of Compounds

May 22, 2024 10:00 AM

Archetype Therapeutics, an AI-native company pioneering the integrative use of generative chemogenomics in drug discovery, announced today that it has discovered compounds for the treatment of early-stage lung adenocarcinoma (esLUAD) by screening billions of compounds from the Enamine REAL Space chemical library and other libraries. These pre-lead drugs are being validated in vitro and in vivo through Archetype-sponsored research conducted at...

Read more

TISSIUM Selected for the French Tech 120 Program

May 22, 2024 8:45 AM

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, confirms its selection for the fifth year in a row in the French Tech 120 Program by joining the class of 2024.Launched in 2019 by the Mission French Tech, the French Tech 120 is a program from the Government to support the 120 most promising French start-ups, who have the potential to become world-class technology leaders.TISSIUM...

Read more

Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders

May 22, 2024 8:12 AM

No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to CommenceInvestor Call Scheduled for today, Wednesday, May 22, at 10:00 am ET to Discuss Potential Impact on PTSD, Depression, Anxiety, Addiction, and ObesityNEW YORK, NY / ACCESSWIRE / May 22, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the complete safety data set from the single dose...

Read more

Tharimmune Announces 1-for-15 Reverse Stock Split

May 22, 2024 7:00 AM

BRIDGEWATER, NJ / ACCESSWIRE / May 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock after the close of trading on The Nasdaq Capital Market ("Nasdaq") on May 24, 2024. Tharimmune's...

Read more

Next Gen Diagnostics and Vanderbilt Report the Use of Whole Genome Sequencing to Detect Transmission of Infection in a Neonatal Intensive Care Unit

May 21, 2024 6:30 PM

WEST PALM BEACH, FL / ACCESSWIRE / May 21, 2024 / Next Gen Diagnostics (NGD) and a team at Vanderbilt University Medical Center (VUMC) today announced the results of a study reporting that comparison of the whole genome sequence (WGS) of bacterial pathogens obtained from surveillance of infants in a neonatal intensive care unit (NICU) revealed substantial transmission of infection not detected by conventional infection control procedures. The...

Read more

Adolore BioTherapeutics Outlines Strategy for its Next Generation, Disease-Modifying, Non-Opioid Analgesic Gene Therapies for the Treatment of Chronic Pain

May 21, 2024 10:00 AM

Development program for the treatment of osteoarthritis (OA) chronic knee pain is fully funded through the first-in-human clinical study by a UG3/UH3 grant awarded by NIH/NINDS HEAL programOngoing progress with IND-enabling studies of ADLR-1001 gene therapy for the treatment of OA chronic knee pain; Additional translational data expected before year-endPlans for data presentations at prominent scientific congresses and publications in premier...

Read more

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

May 21, 2024 9:15 AM

Team composed of former FDA officials and key clinical and regulatory opinion leaders to help provide insight in preparation for collaboration with FDANEW YORK, NY / ACCESSWIRE / May 21, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has formed an Advisory Committee to provide guidance as the company prepares...

Read more

NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform

May 21, 2024 9:00 AM

CLEVELAND, OH / ACCESSWIRE / May 21, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a pioneering biomedical company developing innovative immunotherapies for brain tumor patients, today announced it has submitted a provisional patent for new intellectual property developed at Cedars-Sinai to advance the Company's immunotherapy platform. The patent pertains to the use of a specific protein, known as IDH1, which helps facilitate metabolism in cells in...

Read more

Center Point Bio-Tech Signs National Distribution Agreement

May 20, 2024 12:00 PM

LAS VEGAS, NV / ACCESSWIRE / May 20, 2024 / In anticipation of commercial launch of the AlphaION Point of Care diagnostic platform, Center Point Bio-Tech, LLC ("CP Bio") entered into a non-exclusive distribution agreement with a well-known and highly respected veterinary distributor with over 60 years of sales excellence and logistics expertise to sell and distribute products to veterinary hospitals."Center Point Bio-Tech's development of...

Read more

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

May 20, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product.PF614-MPAR is the Company's...

Read more

Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis

May 20, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 / Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis reflected an increase in plasma MMP-13 and a trend of decreased plasma TGFβ1, consistent with the mechanism of action.The data were orally presented at the...

Read more

QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency

May 17, 2024 2:00 AM

QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality Control Laboratories issued by the Swedish Medical Products Agency (Läkemedelsverket). QuTEM is thereby authorized to perform critical quality control analysis essential for the release of medicines to...

Read more